Cargando…
Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
BACKGROUND: This study aimed to compare the efficacy and safety of vinorelbine plus cisplatin (NP regimen) vs. gemcitabine plus cisplatin (GP regimen) for treatment of metastatic TNBC after failure with anthracyclines and taxanes. MATERIAL/METHODS: A total of 48 patients with metastatic TNBC that fa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629993/ https://www.ncbi.nlm.nih.gov/pubmed/28957036 http://dx.doi.org/10.12659/MSM.905300 |
_version_ | 1783269156827693056 |
---|---|
author | Wang, Junbin Zheng, Rongsheng Wang, Zishu Yang, Yan Wang, Mingxi Zou, Weiyan |
author_facet | Wang, Junbin Zheng, Rongsheng Wang, Zishu Yang, Yan Wang, Mingxi Zou, Weiyan |
author_sort | Wang, Junbin |
collection | PubMed |
description | BACKGROUND: This study aimed to compare the efficacy and safety of vinorelbine plus cisplatin (NP regimen) vs. gemcitabine plus cisplatin (GP regimen) for treatment of metastatic TNBC after failure with anthracyclines and taxanes. MATERIAL/METHODS: A total of 48 patients with metastatic TNBC that failed in anthracyclines and taxanes treatment were enrolled and randomly grouped. Patients in the NP group (n=22) were given 25 mg/m(2) vinorelbine on days 1 and 8 and 25 mg/m(2) cisplatin on days 2–4 of each 21-day cycle, while subjects in the GP group (n=26) were administered 1000 mg/m(2) gemcitabine on days 1 and 8 and 25 mg/m(2) cisplatin on days 2–4 of each 21-day cycle. The treatment response and adverse events were compared between the 2 groups every 2 cycles. RESULTS: The ORR, DCR, and median TTP were 45.5%, 77.3%, and 5 months in the NP group, and 46.2%, 80.8%, and 5.2 months in the GP group, and no significant differences were observed in ORR, DCR, and median TTP between the 2 groups (P>0.05). The major adverse events included grade I–II bone marrow inhibition, gastrointestinal reactions, and phlebitis, and a lower incidence of thrombocytopenia and rash and a higher incidence of phlebitis was found in the NP group than in the GP group (P<0.05). CONCLUSIONS: Either NP or GP regimen is active and tolerated in treatment of metastatic TNBC with anthracyclines and/or taxanes resistance, which may be used as a salvage treatment for metastatic TNBC. |
format | Online Article Text |
id | pubmed-5629993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56299932017-10-13 Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes Wang, Junbin Zheng, Rongsheng Wang, Zishu Yang, Yan Wang, Mingxi Zou, Weiyan Med Sci Monit Clinical Research BACKGROUND: This study aimed to compare the efficacy and safety of vinorelbine plus cisplatin (NP regimen) vs. gemcitabine plus cisplatin (GP regimen) for treatment of metastatic TNBC after failure with anthracyclines and taxanes. MATERIAL/METHODS: A total of 48 patients with metastatic TNBC that failed in anthracyclines and taxanes treatment were enrolled and randomly grouped. Patients in the NP group (n=22) were given 25 mg/m(2) vinorelbine on days 1 and 8 and 25 mg/m(2) cisplatin on days 2–4 of each 21-day cycle, while subjects in the GP group (n=26) were administered 1000 mg/m(2) gemcitabine on days 1 and 8 and 25 mg/m(2) cisplatin on days 2–4 of each 21-day cycle. The treatment response and adverse events were compared between the 2 groups every 2 cycles. RESULTS: The ORR, DCR, and median TTP were 45.5%, 77.3%, and 5 months in the NP group, and 46.2%, 80.8%, and 5.2 months in the GP group, and no significant differences were observed in ORR, DCR, and median TTP between the 2 groups (P>0.05). The major adverse events included grade I–II bone marrow inhibition, gastrointestinal reactions, and phlebitis, and a lower incidence of thrombocytopenia and rash and a higher incidence of phlebitis was found in the NP group than in the GP group (P<0.05). CONCLUSIONS: Either NP or GP regimen is active and tolerated in treatment of metastatic TNBC with anthracyclines and/or taxanes resistance, which may be used as a salvage treatment for metastatic TNBC. International Scientific Literature, Inc. 2017-09-28 /pmc/articles/PMC5629993/ /pubmed/28957036 http://dx.doi.org/10.12659/MSM.905300 Text en © Med Sci Monit, 2017 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Clinical Research Wang, Junbin Zheng, Rongsheng Wang, Zishu Yang, Yan Wang, Mingxi Zou, Weiyan Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes |
title | Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes |
title_full | Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes |
title_fullStr | Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes |
title_full_unstemmed | Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes |
title_short | Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes |
title_sort | efficacy and safety of vinorelbine plus cisplatin vs. gemcitabine plus cisplatin for treatment of metastatic triple-negative breast cancer after failure with anthracyclines and taxanes |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629993/ https://www.ncbi.nlm.nih.gov/pubmed/28957036 http://dx.doi.org/10.12659/MSM.905300 |
work_keys_str_mv | AT wangjunbin efficacyandsafetyofvinorelbinepluscisplatinvsgemcitabinepluscisplatinfortreatmentofmetastatictriplenegativebreastcancerafterfailurewithanthracyclinesandtaxanes AT zhengrongsheng efficacyandsafetyofvinorelbinepluscisplatinvsgemcitabinepluscisplatinfortreatmentofmetastatictriplenegativebreastcancerafterfailurewithanthracyclinesandtaxanes AT wangzishu efficacyandsafetyofvinorelbinepluscisplatinvsgemcitabinepluscisplatinfortreatmentofmetastatictriplenegativebreastcancerafterfailurewithanthracyclinesandtaxanes AT yangyan efficacyandsafetyofvinorelbinepluscisplatinvsgemcitabinepluscisplatinfortreatmentofmetastatictriplenegativebreastcancerafterfailurewithanthracyclinesandtaxanes AT wangmingxi efficacyandsafetyofvinorelbinepluscisplatinvsgemcitabinepluscisplatinfortreatmentofmetastatictriplenegativebreastcancerafterfailurewithanthracyclinesandtaxanes AT zouweiyan efficacyandsafetyofvinorelbinepluscisplatinvsgemcitabinepluscisplatinfortreatmentofmetastatictriplenegativebreastcancerafterfailurewithanthracyclinesandtaxanes |